Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor
Authors:
Open Access
- 26 March 2010
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 21 (10) , 2107-2111
Abstract
Background: We sought to investigate the characteristics and survival rate of patients with gastrointestinal stromal tumor (GIST) associated with other primary malignancies. Patients and methods: A total of 783 patients with GIST were identified from 1995 to 2007. Additional primaries included tumors not considered metastasis, invasion, or recurrence of GIST, nor non-melanoma skin cancer. Data on gender, age at diagnosis, follow-up time after diagnosis, and death were collected. Results: Of the 783 patients with GIST, 153(20%) were identified with at least one additional primary. Patients with additional primaries were more often men (M : F 1.5 versus 1.3) and older (66 versus 53 years). More patients had another cancer diagnosed before (134) than after (52) GIST. Primaries observed before GIST were cancers of the prostate (25), breast (12), esophagus (9), and kidney (7) and melanoma (6). Lung (5) and kidney (5) primaries were the most frequent after GIST. The 5-year survival was 68% for patients with primaries before GIST, 61% for patients with primaries after GIST, 58% for patients with GIST only, and 49% for patients with two or more primaries in addition to GIST (P = 0.002). Conclusions: Approximately 20% of patients with GIST develop other cancers. Inferior median 5-year survival was observed in patients with GIST with two or more other cancers. The etiology and clinical implications of other malignancies in patients with GIST should be investigated.Keywords
Funding Information
- National Institutes of Health
- National Caner Institute (1K23CA109060-05)
This publication has 19 references indexed in Scilit:
- Gastrointestinal stromal tumorSurgical Oncology, 2008
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KITJournal of Clinical Oncology, 2008
- A nonrandom association between gastrointestinal stromal tumors and myeloid leukemiaCancer, 2007
- Gastric and Prostate Adenocarcinoma in a Patient with Metastatic Gastrointestinal Stromal TumorOncology Research and Treatment, 2007
- New developments in gastrointestinal stromal tumorCurrent Opinion in Oncology, 2006
- Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate eraCancer, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Smooth muscle tumors of the gastrointestinal tract: Analysis of prognostic factorsSurgery, 1996
- The Triad of Gastric Leiomyosarcoma, Functioning Extra-Adrenal Paraganglioma and Pulmonary ChondromaNew England Journal of Medicine, 1977
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958